Medtech Insight

LOTUS Wilts? Analysts Pessimistic Over Further Delays in Boston Scientific's TAVR Return

29 Nov 2017

• By Catherine Longworth

Boston Scientific has delayed commercialization of its troubled LOTUS Edge Aortic Valve System, which was recalled from the market earlier this year. The company was due to reintroduce the system in Europe in the fourth quarter of 2017 and by mid-2018 in the US. It's the third time Boston Scientific has pushed back Lotus, prompting the belief the device might not make it to market at all.

withered lotus flower in pond — Does this third delay spell the end of Boston Scientic's Lotus TAVR system?

Boston Scientific Corp has delayed commercialization of its troubled Lotus transcatheter aortic valve business citing ongoing performance issues with the mechanical delivery system. This is the third time the company has delayed timing of Lotus, prompting the belief the TAVR system's days are numbered.

Boston Scientific initiated a worldwide voluntary removal of the LOTUS and LOTUS Edge Aortic Valve Systems in February following reports...